Topic

ACRS

A collection of 1 issue

Aclaris Therapeutics Upgraded to Buy with $20 Target

Aclaris Therapeutics (ACRS) sees positive upgrade to Buy by H.C. Wainwright, following a lucrative exclusive license agreement. Price target set at $20.